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for renal artery fibromuscular dysplasia
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Joseph J. Naoum, MD, and Alan B. Lumsden, MD, Houston, Tex
Background: Percutaneous intervention for symptomatic renal artery fibromuscular dysplasia (FMD) has replaced surgical
therapy as first-line treatment. This study evaluates the factors that impact long-term anatomic and functional outcomes
of endovascular therapy for symptomatic renal artery FMD.
Methods: Records of patients who underwent renal artery angioplasty for FMD between January 1990 and December
2007 were retrospectively analyzed. Indication for intervention was poorly controlled hypertension (diastolic blood
pressure >90 mm Hg or systolic blood pressure >140 mm Hg, or both, taking >2 antihypertensive medications).
Twenty-nine women (average age, 45 years [range, 18-80]; 86% with a history of hypertension <8 years) underwent 38
attempted interventions. Sixty-six percent of contralateral kidneys were normal (31% had a <60% stenosis), 13% had
>60% stenosis, and the remainder were nonfunctioning or absent. Creatinine was >1.5 mg/dL in 4%, 24% had
hyperlipidemia, 17% had metabolic syndrome, and 4% were considered diabetic.
Outcomes: All interventions were successfully performed. Stent placement was required in 13% for technical failure and
flow-limiting dissection. Seventy-three percent of these lesions were in the proximal renal artery, with the remainder in
the middle renal artery. Technical success (<30% residual stenosis) was achieved in all vessels. There were no
periprocedural or 90-day deaths. The procedurally related complication rate was 8%. Median follow-up was 2 years. All
patients were alive at follow-up. Primary and assisted primary patency rates were 66% and 87% at 5 years. Restenosis was
considered a 50% reduction in luminal area on angiography during follow-up. The restenosis rate was 28% at 5 years (10
vessels underwent repeat percutaneous intervention). Immediate clinical benefit was seen in hypertension in 72%
(improved or cured <3 months) and was maintained in 73% at 5 years by life-table analysis. Proportional hazard analysis
showed the predictors of long-term clinical benefit were duration of hypertension <8 years, creatinine <1.5 mg/dL,
ipsilateral kidney size >9 cm, functional status of the contralateral kidney, a fasting blood glucose <110 mg/dL,
triglycerides <150 mg/dL, and high-density lipoprotein >50 mg/dL. Neither age <50 years nor statin administration
appeared significant.
Conclusions: Percutaneous endovascular intervention for clinically symptomatic FMD in the renal arteries is technically
successful, safe, and durable. Most patients have immediate clinical benefit, with continued long-term results out to 5
years. It appears that the presence of existing renal pathology and markers of prediabetic state are associated with
recurrence of hypertensive symptoms. ( J Vasc Surg 2008;48:865-71.)Fibromuscular dysplasia (FMD) can result in significant
hypertension in women aged between 15 and 50 years old
but only accounts for 10% of cases of renovascular hyper-
tension.1 First described in 1938,2 FMD frequently involves
the distal main renal artery and its branches.1 Medial fibropla-
sia represents the most common dysplastic lesion. Medial
hyperplasia may be indistinguishable angiographically from
intimal fibroplasia. Intimal fibroplasia occurs in 10% of pa-
tients with arterial fibrodysplasia. Adventitial (periarterial) hy-
perplasia is the rarest type of fibrodysplastic lesion.
Although FMD has been shown to affect multiple
arterial beds, the frequency of involvement in renal arteries
is 60% to 70%, with bilateral disease occurring in 35% of
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doi:10.1016/j.jvs.2008.05.030patients. The natural history of renal FMD is progression in
up to 37% of patients,3 but this progression only rarely
results in occlusion of the renal artery.4 Patients with FMD
do demonstrate a significant decrease in mean cortical
thickness and reduced renal length compared with similar
patients with essential hypertension. As many as 63% of
patients with FMD experience a loss of renal mass, but the
incidence of renal failure remains remarkably low.3,5 Renal
artery atherosclerosis, in contrast, is a significant cause of
progressive renal dysfunction leading to ischemic nephrop-
athy and loss of functioning renal mass.6
The main impetus for the treatment of FMD is control
of hypertension and its attendant complications. The treat-
ment for most patients can be primarily managed medically.
Revascularization is reserved for those patients who have
recent onset of hypertension (1 year), with the primary
goal to cure the hypertension, those in whom blood pres-
sure control has proved difficult, those intolerant of antihy-
pertensive therapy, those who are not compliant with their
antihypertensive medication, and those who have demon-
strated a loss of renal volume leading to a diagnosis of
ischemic nephropathy.7
The primary mode of intervention is by balloon angio-
plasty, with surgery reserved for recalcitrant lesions. Few
865
JOURNAL OF VASCULAR SURGERY
October 2008866 Davies et alreports, however, address the factors that affect the long-
term durability or clinical effectiveness of percutaneous
transluminal renal angioplasty (PTRA) for renal artery
FMD. The purpose of this study is to evaluate the factors
that influence the long-term anatomic and functional out-
comes of endovascular therapy for symptomatic renal artery
FMD.
METHODS
Study design. We performed a retrospective analysis
of records from patients who underwent PTRA for all
causes between January 1990 and December 2007, and
those with FMD of the main renal artery were identified.
Patients with aneurysmal disease and branch vessel disease
were excluded. Indication for intervention was poorly con-
trolled hypertension, defined as diastolic blood pressure
(DBP)90mmHg or systolic blood pressure (SBP)140
mmHg, or both, taking 2 antihypertensive medications.
For each patient, demographics, existing comorbid condi-
tions, and risk factors for atherosclerosis were identified.
Freedom from recurrent hypertension and factors influenc-
ing clinical benefit were measured.
Treatment algorithm. Patients with hypertension
underwent a diagnostic study to identify the presence of
renal artery stenosis. Procedures were performed within a
service line, and interventionalists were drawn from vascu-
lar surgery, interventional cardiology, and interventional
radiology. This diagnostic study consisted of standard an-
giography, magnetic resonance angiography (MRA), renal
isotope scan, or duplex ultrasound (DUS) imaging. The
DUS criteria to identify renal artery stenosis has been
previously described.8-10 Angiography was performed in
the presence of clinical criteria as defined by Rundback et al11
and a60% stenosis onDUS orMRAor a positive renal scan.
The angiographic analysis was generally performed
through a femoral or transaxillary approach. The lesions
were crossed with a soft, atraumatic guidewire through an
SOSOmni or Simmons catheter (Angiodynamics, Queens-
bury, NY). Balloon angioplasty was performed under sys-
temic heparinization (40 to 60 U/kg intravenously), with
the use of a 0.035-inch guidewire and 4- to 7-mmballoons.
A balloon size 10% larger than the renal artery diameter was
typically selected. Guiding catheters were used when extra
support was deemed necessary. Primary stenting was not
used in this series. Stenting was only used for technical
failure and flow-limiting dissection.
Interventions were performed in patients with renal
artery stenosis50% by angiography, regardless of comor-
bidities. The treatment of patients not categorized into the
clinical criteria referenced was managed medically. Non-
functioning kidneys were not treated. In the presence of
bilateral disease, the clinical criteria for treatment of both
kidneys were the same as those for solitary renal artery
stenosis. Bilateral 50% disease was treated at the same
setting.
Patients were followed up at 6-month intervals after the
procedure. Blood pressure, serum creatinine level, and
number of antihypertensive medications were identifiedduring these intervals. To assess postprocedural patency,
each patient had at least one DUS study 1 month, a
second at 6 months, and a DUS evaluation every 6 months
thereafter. If the DUS showed 60% stenosis and the
patient had recurrent symptoms of poorly controlled hy-
pertension (DBP90mmHg or SBP140mmHg, or an
increase in antihypertensive medications2), angiography
was performed and restenosis was treated if it was 50%.
Median follow-up was 2 years (mean, 3.3; range 0.7-14.4
years) with a median of 4 DUS scans (range, 2-98 scans).
Definitions. The definitions used in the study are as
follows:
● Coronary artery disease was defined as a history of
angina pectoris, myocardial infarction, congestive
heart disease, or prior coronary artery revasculariza-
tions.
● Cerebrovascular disease included a history of stroke,
transient ischemic attack, or carotid artery revascular-
ization.
● Hypercholesterolemia was defined as a fasting choles-
terol level 200 mg/dL.
● Diabetes was defined as a fasting plasma glucose level
110 mg/dL or an HbA1c7%. Patients with diabe-
tes were characterized as having insulin-dependent
diabetes mellitus or non-insulin-dependent diabetes
mellitus.
● Hypertension was defined as a SBP 140 mm Hg or
DBP 90 mm Hg on three occasions during a
6-month period.
● Metabolic syndrome was defined as previously de-
scribed,12 consisting of insulin resistance or impaired
glucose tolerance, hypertension, dyslipidemia, and ab-
dominal obesity, with the exception of abdominal
circumference, which was not routinely recorded. We
substituted a body mass index score30.0 kg/m2 as a
positive score instead of an abdominal circumference
102 cm for men or 88 cm for women.
● An elevated serum creatinine level was defined as1.5
mg/dL on two consecutive values during a 3-month
period.
● Chronic renal insufficiency was defined as a persistent
serum creatinine level 1.5 mg/dL for 6 months.
● Estimated glomerular filtration rate (eGFR) was de-
fined as 186.3 serum creatinine1.154 age0.203
0.742 (if female)  1.212 (if African American). The
baseline serum creatinine was the value recorded closest
to the procedure.
Patients were considered to have a “nonfunctioning
kidney” if any two of the following local criteria used at our
institution during the study period were met: (1) a DUS
scan identified a pole-to-pole length of 9 cm, with no
renal flow in the main renal artery and parenchymal peak
systolic velocity 10 cm/s, (2) surgically or congenitally
absent kidney, or (3) no visible nephrogram on contrast
arteriogram. The renal resistive index was defined from
DUS imaging as (1  [end diastolic velocity/peak systolic
velocity])  100.
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nosis of 30%. Failures were residual stenosis 30%, by
angiographic measurement, including lesions unable to be
dilated or crossed, and occlusion30 days. Restenosis was
considered a 60% reduction in luminal area as determined
by DUS imaging or a 50% reduction in luminal area as
determined by angiography, or both, during follow-up. A
death30 days of the procedure was considered procedur-
ally related.
Response in the hypertensive patient was defined as
follows: “Cured” patients became normotensive after inter-
vention (DBP 90 mm Hg and SBP 140 mm Hg)
without medications. “Improved” patients became normo-
tensive after intervention (DBP90 mmHg or SBP140
mm Hg, or both) on the same (or reduced) number of
medications, or had a DBP 15 mmHg below baseline with
the same or reduced number of medications. “No effect”
patients had no change or did not meet these criteria for
cure or improvement of presenting hypertension after in-
tervention and were considered a treatment failure. For the
purposes of this report, responders were patients in whom
an improved or cured hypertension was demonstrated 3
months of intervention, and nonresponders were patients
in whom no effect on their hypertension was demonstrated.
Recurrence of hypertension was defined as a recurrence of
DBP 90 mm Hg or SBP 140 mm Hg, or a 20%
increase of postprocedural baseline DBP that was not treat-
able by repeat angioplasty.11
Statistical analysis. We performed our analysis on an
intention-to-treat basis. Measured values are reported as
percentages or means  1 standard deviation. Survival,
cumulative patency, and clinical benefit rates are calculated
using life-table analysis and reported using the Society for
Vascular Surgery criteria. Standard errors are reported in
life-table analyses. The log-rank test was used to determine
differences between life tables. The Cox proportional haz-
ards model was used for the time-dependent outcomes of
death, patency, and long-term freedom from recurrent
hypertension. The proportional hazards assumption was
checked and confirmed for the significant covariates using
log (-log [survival]) curves. Logistic regression models
were used for outcomes measured shortly after the proce-
dure, including complications and short-term clinical ben-
efits. The dependence of each covariate on the outcome
was first checked separately using the 2 test. Covariates
with the significance level of P  .10 were included in the
multivariate stepwise analysis.
RESULTS
Patient population. The study comprised 29 women
who were a mean age of 45 years (range 18-80 years), with
69% were aged50 years. A total of 38 interventions were
attempted (9 were for bilateral lesions). A history of hyper-
tension 8 years was present in 86%, 24% had hyperlipid-
emia, 17% had metabolic syndrome, 4% were considered
diabetic, and 4% had a serum creatinine level1.5 mg/dL
(Table I). Sixty-six percent of contralateral kidneys werenormal (31% had a60% stenosis), 13% had60% stenosis,
and the remainder were nonfunctioning or absent (Table II).
Immediate outcomes (<3 months). Of the 38
planned interventions, technical success, as defined by
30% residual stenosis on angiographic imaging, was
achieved in all vessels; however, placement of a stent oc-
curred in 13% because of technical failure and flow-limiting
dissection. The proximal renal artery was the location for
73% of these lesions, with the remainder in the middle renal
artery. No branch vessels of the main renal artery were
treated. There were no periprocedural 30-day or 90-day
deaths.
The procedure-related complication rate was 8%; all
were minor and included one patient each with groin
hematoma, groin pseudoaneurysm, and arteriovenous fis-
tula. Hypertension was “improved” or “cured”3months
of intervention in 72% of the patients (Table III). Signifi-
cant differences were seen in the population of responders
vs nonresponders in duration of hypertension (8 years),
presence of hyperlipidemia, worsening stage of chronic
kidney disease, smaller ipsilateral kidney, contralateral renal
artery stenosis (50%), and bilateral higher resistive indices
within the kidney (Tables I and II). These factors all
correlated with response. When we specifically looked at
Table I. Patients characteristics, indications, and
comorbidities by response to treatment
Characteristics Response
No
Response P
Patients, No. 21 8 . . .
Kidneys treated, No. 27 11 . . .
Bilateral disease, No. 6 3 . . .
Age
Mean average  SD, years 47  16 43  22 .02
50 years, % 71 63 .09
Hypertension duration 8
years, % 86 63 .05
Blood pressure, mean  SD
mm Hg
Systolic 169  20 180  36 .2
Diastolic 92  13 91  14 .3
Antihypertensive drugs,
mean  SD 2  1 3  1 .5
Comorbidities, %
Smoking history 19 13 .09
Diabetes mellitus 5 0 .05
Hyperlipidemia 19 38 .05
Metabolic syndrome 14 25 .05
Cerebrovascular 10 13 .2
Creatinine 1.5 mg/dL 5 13 .05
Hormone replacement
therapy 10 8 .12
Metabolic syndrome variables, %
Hypertension 100 100
Body mass index 27 kg/m2 28 13 .05
Fasting blood glucose 110
mg/dL 19 25 .05
HDL 50 mg/dL 13 35 .05
Triglycerides 150 mg/dL 19 25 .05
HDL, High-density lipoprotein; SD, standard deviation.metabolic syndrome as a discrete variable, it was not signif-
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were identified; however, when the group was stratified,
more patients in the nonresponder group were diagnosed
as having metabolic syndrome, and the predominant fea-
tures were abnormal fasting blood glucose, low high-density
lipoprotein (HDL), and elevated triglycerides (Table I).
Outcomes (>3 months). All patients were alive at
follow-up. No chronic renal impairment developed during
follow-up. Primary and assisted primary patency rates de-
termined by serial DUS imaging were 66% and 87% at 5
years (Fig,A). Assisted primary and secondary patency rates
were equal (Fig, A). The restenosis rate was 28% at 5 years
(Fig, B). Stent placement did not influence patency, reste-
nosis, or symptom recurrence. Ten vessels underwent re-
peat percutaneous intervention for recurrent symptoms.
Reintervention by balloon angioplasty for restenosis in
those patients with recurrent symptoms, defined as poorly
Table II. Kidney disease, functional parameters, and ipsila
to treatment
Variable R
Kidney stage, %
1 (eGFR 90a)
2 (eGFR 60-89a)
3 (eGFR 30-59a)
4 (eGFR 15-29a)
5 (eGFR 15a or dialysis)
Functional parameters
Creatinine, mean  SD mg/dL 0.9
eGFR, mean  SDa 78.0
eGFR 30a, %
eGFR 30-60a, %
eGFR 60a, %
Ipsilateral kidney variables
Kidney size, mean  SD cm 10.4
Resistive index, mean  SD 0.65
Contralateral kidney anatomy, %
Normal
Stenosis (60%)
Nonfunctioning
Contralateral kidney variables
Kidney size, mean  SD cm 9.6
Resistive index, mean  SD 0.66
eGFR, Estimated glomerular filtration rate; SD, standard deviation.
aThe eGFR is calculated as mL/min/1.73 m2.
Table III. Outcomes according to response to treatment
Outcome Response No response P
Immediate clinical benefit, %
Deterioration 0 0
No Change 0 100 .05
Improved 81 0 .05
Cured 19 0 .05
Long-term outcomes, %
Vessel occlusion 0 38 .05
Vessel restenosis 14 13 .2
Absolute recurrence 14 25 .05
Ipsilateral reintervention 14 13 .2controlled hypertension (DBP 90 mm Hg or SBP 140mm Hg or an increase in antihypertensive medications of
2), was successful in all cases.
Development of restenosis was associated with low
HDL levels (50 mg/dL, female; relative risk [RR], 2.35;
95% confidence interval [CI], 1.32-4.52; P  .004); ele-
vated triglycerides levels (150 mg\dL; RR, 2.2; 95% CI,
1.84-2.86; P .004); eGFR30 mL/min/1.73 m2 (RR,
1.74; 95% CI, 1.09-3.24; P  .004); and age 55 years
(RR, 2.78 (95% CI, 1.51-131.50; P  .003).
In response to therapy, 72% of patients demonstrated
immediate clinical benefit, with improved or cured hyper-
tension 3 months of procedure. This clinical benefit was
maintained in 71%  9% of patients at 5 years by life-table
analysis (Fig, C). When only those patients who demon-
strated immediate clinical benefit were analyzed, clinical
benefit was maintained in 73%  9% at 5 years by life-table
analysis. A significant relationship was found between the
presence of restenosis and loss of clinical benefit (odds
ratio, 0.008; 95% CI 0.0004-0.167; P  .0001). Angio-
graphically significant restenosis was found in only 64% of
patients with recurrent symptoms (odds ratio, 0.0084; 95%
CI, 0.0004-0.1658). We did not encounter any patients
with asymptomatic restenosis during follow-up.
Proportional hazard analysis showed the predictors of
long-term clinical benefit were duration of hypertension
8 years (RR, 1.23; 95% CI, 1.01-2.98, P  .02), eGFR
60 mL/min/1.73 m2 (RR, 26.5; 95% CI, 18.1-34.5, P
.01), ipsilateral kidney size 9 cm (RR, 1.41; 95% CI,
1.1-3.3; P  0.03), status of the contralateral kidney (RR,
1.53; 95% CI, 1.1-1.96, P  .04), a fasting blood glucose
and contralateral variables according to response
se No response P
38 .1
25 .05
25 .05
13 .05
0
.01 1.3  0.1 .05
.1 74.6  4.3
13 .05
12 .05
75 .2
.04 9.7  0.05 .05
.004 0.70  0.01 .05
50 .05
50 .05
0 .05
.02 9.6  0.1 .3
.005 0.68  0.01 .05teral
espon
29
52
19
0
0
 0
 1
0
24
76
 0
 0
71
19
10
 0
 0110 mg/dL (RR 1.53, 95% CI 1.17-2.34, P  .04),
figure.
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P  .004), and HDL 50 mg/dL (RR 3.89, 95% CI
2.12-6.39, P  .024); the latter three are markers of the
prediabetic state and associated with metabolic syndrome.
Neither age 50 years nor administration of statins ap-
peared to be significant. Categorization of the status of the
contralateral kidney by occlusion of the renal artery vs
surgically absent kidney did not influence freedom from
recurrent symptoms.
DISCUSSION
PTRA has become the treatment of choice for patients
with renal artery FMD limited to the main renal artery.3
Most these patients have medial fibroplasia. In the current
cohort of patients with FMD and hypertension, PTRA was
technically successful and was associated with no major
complications and a low morbidity rate. There was a 100%
technical success rate, whereas published reports indicate
technical success rates for PTRA in these circumstances of
83% to 100%.13-19 Success rates with open revascularization
are 89% to 97%. No anatomic injuries or acute functional
injuries occurred. In contrast with the FMD population,
acute functional injury, defined as a persistent increase in
the serum creatinine level of0.5 mg/dL at 1 month after
the procedure, associated with atheroembolism during re-
nal intervention for atherosclerotic disease, is now recog-
nized as an important clinical problem.20-22 Patient survival
in this cohort was 100% during follow-up, no new patients
developed chronic renal impairment, and those with a
pre-existing serum creatinine level 1.5 mg/dL did not
demonstrate worsening of renal function.
We had a 100% technical success rate after intervention
according to angiographic criteria. One caveat on this result
should be mentioned. Currently, many authors now rec-
ommend that because the degree of stenosis associated
with FMD cannot always be estimated by angiographic
appearance alone, translesional pressure measurements or
immediate postprocedural duplex sonography, or both,
should be performed to better describe technical success.
The current study showed a cumulative patency rate 87%
at 5 years. Restenosis developed in 14% of the vessels, with an
actuarial restenosis rate of 28% at 5 years. Reintervention by
balloon angioplasty for restenosis was successful in all cases.
Reported restenosis rates after PTRA for FMD are 7% to
27%.13-19Clinical factors associatedwith restenosis after initial
PTRA, include increased body mass index and duration and
degree of hypertension.23 We did not identify either factor as
a significant variable in the development of restenosis.
Oertle et al24 have shown that about one-third of
patients treated by PTRA for FMD who subsequently
return during follow-up with deterioration of or recurrent
arterial hypertension have no angiographic demonstrable
restenosis, whereas 15% of patients without deterioration of
or recurrent arterial hypertension have angiographic de-
monstrable restenosis. Our data confirmed that approxi-
mately one-third of patients with recurrent symptoms do
not demonstrate restenosis and that the presence of reste-Fig. A, Life-table analysis of primary and assisted primary patency
of the renal vessels intervened on for symptomatic fibromuscular
dysplasia. B, Life-table analysis of freedom from restenosis. C, Life-
table analysis of freedom from recurrent hypertension. Recurrence
was defined as a recurrence of diastolic blood pressure90mmHg
or systolic blood pressure 140 mm Hg or a 20% increase of
postprocedural baseline diastolic blood pressure that was not treat-
able by repeat angioplasty. Values are mean standard error of the
mean. The number at risk at each time interval is shown below eachnosis in asymptomatic patients is very low. However, the
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should prompt early reimaging of the renal vessel and
should prompt more frequent duplex imaging.
Diabetes and insulin resistance have been shown to be
independent predictors of early restenosis after coronary
stenting.25-28 In the current study, dyslipidemia (lowHDL
and high triglyceride levels), low eGFR (30 mL/min/
1.73 m2), and patients aged 55 years were factors associ-
ated with the development of restenosis.
The clinical success, defined as cured or improved
hypertension after PTRA, was 72%. Hypertension cure
rates of 14% to 59% and hypertension improvement rates of
21% to 63% have been reported.13-19 The incidence of “no
effect” with endoluminal intervention ranges from 7% to
30%.3 With open surgery, cure of hypertension can be
obtained in 33% to 63% of patients, with improvements in
hypertension noted in 24% to 57%. The incidence of failure
(ie, “no effect” on hypertension) is 3% to 33%. Successful
outcome appears to be associated with an age 50 years,
the absence of associated coronary and carotid stenosis, and
duration of hypertension of8 years. In the current study,
we identified the duration of hypertension as a significant
factor related to successful outcome. However, we also
identified an association with decreased long-term clinical
benefit and a cluster of variables associated with prediabetic
state, including fasting blood glucose 110 mg/dL, trig-
lycerides 150 mg/dL, and HDL 50 mg/dL. This is a
novel finding. An important finding in this cohort was that
statin therapy did not influence outcomes.
These data would suggest that surveillance for and
aggressive correction of both the prediabetic state and
dyslipidemic should be considered in patients presenting
with symptomatic FMD. There are limitations to the cur-
rent study. The patient number is relatively small but does
represent one of the largest series in the literature. We only
treated main renal artery disease and did not include pa-
tients with branch vessel disease.
CONCLUSION
Percutaneous endovascular intervention for clinically
symptomatic FMD in the main renal artery is technically
successful and safe. There are excellent cumulative patency
and low restenosis rates. Most patients experience an im-
mediate clinical benefit, with continued long-term results in
70%. It appears that the presence of existing renal pathology
and markers of prediabetic state are associated with restenosis
and with recurrence of hypertensive symptoms.
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